AEON Biopharma, Inc.
About AEON Biopharma, Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$39.2M
- Total assets
- $5.6M
- Market cap
- $19.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.8M
- Operating income
- -$12.8M
- Income tax
- $0
- Net income
- -$39.2M
- EPS (basic)
- $-3.95
- EPS (diluted)
- $-3.95
Balance sheet
- Total assets
- $5.6M
- Current assets
- $3.4M
- Total liabilities
- $60.6M
- Current liabilities
- $6.9M
- Shareholders’ equity
- -$55.0M
Cash flow
- Operating cash flow
- -$17.3M
- Investing cash flow
- -$4.0K
- Financing cash flow
- $20.3M
- Net cash flow
- $3.0M
Statements via Polygon.io (SEC filings)
- Market cap
- $19.0M
- EPS (diluted)
- $-3.95
- Shares outstanding
- 26.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.2M.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AEON Biopharma, Inc..
Write a review
News about AEON Biopharma, Inc.
News & sentiment via Polygon.io
